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Common variable immunodeficiency (CVID), 
is a heterogeneous group of disorders charac­
terized by hypogammaglobulinemia associated 
with B cell, T cell, and dendritic cell defects (De 
Gast et al., 1980; Reinherz et al., 1981; Levy 
et al., 1998; Cunningham­Rundles and Bodian, 
1999; Bonhomme et al., 2000; Cunningham­
Rundles et al., 2001; Bayry et al., 2004; Park 
et al., 2008; Paquin­Proulx et al., 2013b). The 
clinical picture is characterized by recurrent 
bacterial infections predominantly caused by 
Streptococcus pneumoniae, Klebsiella pneumoniae, 
and Haemophilus influenzae (Van der Hilst et al., 
2002; Park et al., 2008; Hong et al., 2010). Sev­
eral genetic mutations associated with CVID 
have been identified only in 15–20% of CVID 
cases (Park et al., 2008). In particular, mutations 
in the TNFRSF13B (TACI; Castigli et al., 2005), 
ICOS (Grimbacher et al., 2003), CD19 (van 
Zelm et al., 2006), CD20 (Kuijpers et al., 2010), 
and CD81 (van Zelm et al., 2010) genes have 
been previously described.
Hypogammaglobulinemia is defined by the 
plasmatic concentration of IgG <4.9 mg/ml, 
and the current treatment consists of intrave­
nous IgG (IVIG) replacement every 3–4 wk 
(Cunningham­Rundles, 2010) with the goal of 
protecting the patients against extracellular 
pathogen infections. Although protection against 
extracellular bacteria is commonly assigned to 
B cell responses with the production of high 
affinity antibodies, adequate CD4 T cell func­
tion is essential for optimal B cell maturation 
and antibody production, activation of macro­
phages, and/or recruitment of effector cells to 
the site of infection (Bloom and Bennett, 1970; 
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In the present study, we have investigated the functional profile of CD4 T cells from patients 
with common variable immunodeficiency (CVID), including production of cytokines and prolif-
eration in response to bacteria and virus-derived antigens. We show that the functional im-
pairment of CD4 T cells, including the reduced capacity to proliferate and to produce IFN- 
and IL-2, was restricted to bacteria-specific and not virus-specific CD4 T cells. High levels of 
endotoxins were found in the plasma of patients with CVID, suggesting that CD4 T cell dys-
function might be caused by bacterial translocation. Of note, endotoxemia was associated with 
significantly higher expression of programmed death 1 (PD-1) on CD4 T cells. The blockade of 
the PD-1–PD-L1/2 axis in vitro restored CD4 T cell proliferation capacity, thus indicating that 
PD-1 signaling negatively regulates CD4 T cell functions. Finally, we showed that intravenous 
immunoglobulin G (IVIG) treatment significantly reduced endotoxemia and the percentage of 
PD-1+ CD4 T cells, and restored bacteria-specific CD4 T cell cytokine production and prolifera-
tion. In conclusion, the present study demonstrates that the CD4 T cell exhaustion and func-
tional impairment observed in CVID patients is associated with bacterial translocation and that 
IVIG treatment resolves bacterial translocation and restores CD4 T cell functions.
© 2014 Perreau et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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levels of programmed death 1 (PD­1) molecule. In addition, 
the blockade of the PD­1–PD ligand 1/2 (PDL­1/2) pathway 
was associated with the restoration of bacteria­specific CD4 
T cell proliferation, thus demonstrating that the functional 
impairment of bacteria­specific CD4 T cells was caused by 
PD­1–associated cell exhaustion. Of note, we also showed that 
all untreated CVID patients have detectable levels of endotox­
ins, i.e., a marker of bacterial translocation, and that endotox­
emia inversely correlated with IgG concentration. Finally, 
longitudinal analyses of CVID patients demonstrated that IVIG 
treatment significantly reduced endotoxemia and PD­1 expres­
sion on CD4 T cells, and restored bacteria­specific CD4 T cell 
cytokine production and proliferation. The present study pro­
vides new insights in the mechanisms responsible for the CD4 
T cell functional impairment in CVID patients and indicates 
that IVIG treatment results in resolution of bacterial transloca­
tion and restoration of CD4 T cell functions.
RESULTS
Bacteria-specific CD4 T cells from CVID patients  
are functionally impaired
In the present study, 26 CVID patients and 30 healthy individ­
uals have been enrolled (Tables 1 and 2). It is important to 
David, 1973; Nathan et al., 1983; Ishihara et al., 1986; Parker, 
1993; Ye et al., 2001; McHeyzer­Williams and McHeyzer­
Williams, 2005). Several CD4 T cell abnormalities have been 
documented in CVID patients (Sneller and Strober, 1990; 
Aukrust et al., 1994; Cunningham­Rundles and Bodian, 
1999; Giovannetti et al., 2007) and include the reduction of 
CD4 T cell count, inversion of CD4/CD8 ratio, and func­
tional alterations such as reduced proliferation capacity and/or 
impaired production of cytokines (Sneller and Strober, 1990; 
Aukrust et al., 1994; Cunningham­Rundles and Bodian, 
1999; Giovannetti et al., 2007). However, the causes of the 
CD4 T cell functional impairment remains unknown.
In the present study, we hypothesized that the recurrent 
bacterial infections occurring in CVID patients may lead to 
secondary CD4 T cell deficiency. To test this hypothesis, we 
have performed a comprehensive investigation of the func­
tional profile of CD4 T cells including the capacity to produce 
cytokines, such as TNF, IFN­, IL­2, and IL­17A, and/or to 
proliferate in response to bacteria­ and virus­derived antigens.
We demonstrate that bacteria­specific but not virus­specific 
CD4 T cells were impaired in both their capacity to produce 
IFN­ and IL­2 and to proliferate. Interestingly, bacteria­ 
specific but not virus­specific CD4 T cells expressed higher 
Table 1. Characteristics of CVID patients
Subjects Gender Year of birth Baseline IgG Baseline IgA Baseline IgM CD4 count CD8 count CD19 cell count CD4/CD8 ratio
mg/ml mg/ml mg/ml % cells/µl % cells/µl % cells/µl
CVID-1 F 1962 4.9 <0.06 0.19 31.9 559 33.2 581 12.1 221 0.96
CVID-2 F 1971 1.34 <0.06 <0.17 60 nd 15 nd 10 nd 4.00
CVID-3 M 1949 1.04 0.1 1.63 36.6 1096 21.2 710 12 411 1.73
CVID-4 F 1976 1.75 0.09 0.56 48 941 28 552 11 221 1.70
CVID-5 M 1973 3.63 <0.06 0.66 37 1463 23.2 917 27.7 1180 1.60
CVID-6 M 1949 3.46 0.24 0.43 nd nd nd nd 4.2 33 nd
CVID-7 F 1965 0.15 <0.06 <0.17 32 793 46 1141 6 175 0.70
CVID-8 M 1972 0.84 <0.06 <0.17 19.6 624 51.4 1636 6.5 203 0.38
CVID-9 F 1977 1.12 <0.06 1.03 50.1 723 19.6 283 9.3 138 2.55
CVID-10 F 1948 <0.5 <0.06 <0.17 nd nd nd nd nd nd nd
CVID-11 F 1992 1.94 <0.06 0.43 23.3 505 24.2 524 15.4 332 0.96
CVID-12 F 1953 1.57 0.19 0.18 32.9 389 24.5 289 4.4 52 1.35
CVID-13 M 1982 3.67 0.17 0.21 49.5 746 40 603 4.2 91 1.24
CVID-14 M 1958 0.83 <0.06 0.19 nd nd nd nd nd nd nd
CVID-15 M 1941 2.6 <0.06 <0.17 28 632 43 994 11 253 0.64
CVID-16 M 1992 1.3 <0.25 <0.17 33 355 31 334 13 139 1.06
CVID-17 F 1980 <0.5 <0.06 <0.17 nd nd nd nd nd nd nd
CVID-18 F 1983 4.4 <0.06 <0.17 54 1091 26 532 11 221 2.05
CVID-19 M 1958 1.54 <0.06 <0.17 27 380 50 700 4 56 0.54
CVID-20 M 1981 0.6 <0.25 <0.17 42 686 35 579 10 165 1.18
CVID-21 F 1946 1.95 <0.06 <0.17 41 nd 37 nd <1 nd nd
CVID-22 M 1975 1.9 <0.06 0.2 36 366 22 221 15 148 1.66
CVID-23 F 1986 4.4 0.55 0.76 49 1107 30 683 9.3 207 1.62
CVID-24 F 1973 0.8 <0.25 <0.17 38 296 40 316 10 82 0.94
CVID-25 M 1980 1.9 0.8 0.7 37 nd 36 nd 9 nd 1.02
CVID-26 M 1957 4.9 0.77 1.22 47 789 35 585 10 169 1.35
nd, not determined.
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CD4 T cells were significantly reduced in CVID patients as 
compared with healthy individuals (P = 0.0006 and P = 
0.003, respectively; Fig. 1 C and not depicted). However, 
the frequencies of both bacteria­specific and virus­specific 
CD4 T cells producing TNF were not significantly different 
between the two groups (P = 0.6841 and P = 0.8202, re­
spectively; Fig. 1 C), and only a trend toward lower fre­
quency of bacteria­specific CD4 T cells producing IL­17A 
was observed in CVID patients (P = 0.2413; Fig. 1 C). Of 
note, the capacity of bacteria­specific CD4 T cells to pro­
duce IL­4 or IL­21 was also evaluated by flow cytometry. 
The frequencies of IL­4– or IL­21–producing bacteria­
specific CD4 T cells were very low and not significantly 
different between CVID patients and healthy subjects (P = 
0.3950 and P = 0.8714, respectively; data not shown). The 
proliferation capacity of bacteria­specific but not virus­
specific CD4 T cells was also significantly reduced (P < 
0.0001 and P = 0.8745, respectively) in CVID patients as 
compared with healthy subjects (Fig. 1, D and E), thus 
demonstrating that bacteria­specific CD4 T cells of CVID 
patients are selectively dysfunctional.
It is also important to mention that no differences be­
tween the cytokine profile or the proliferation profile of 
S. pneumoniae/K. pneumoniae and S. aureus and E. coli were ob­
served (unpublished data). The absence of difference in the 
underscore that none of the CVID patients investigated in the 
present study for phenotypic and functional analyses and for 
the measures of endotoxins in plasma had documented active 
bacterial infections at the time of blood collection. In this re­
gard, C reactive protein (CRP) was measured in 18 patients at 
the time of the study. CRP levels were <10 mg/liter (cut­off 
of the method in the central laboratory of the hospital) in 
17 out of 18 patients and slightly positive, i.e., 11.5 mg/liter, 
in one patient.
To evaluate the functional profile of bacteria­specific and 
virus­specific CD4 T cells of CVID patients, blood mononu­
clear cells of CVID patients (n = 12) and healthy individuals 
(used as control; n = 30) were stimulated with bacteria­ 
derived antigens from Staphylococcus aureus, S. pneumoniae, 
Streptococcus agalactiae (i.e., group B Streptococcus), Pseudomonas 
aeruginosa, K. pneumoniae, and two serotypes of Escherichia coli 
or virus­derived antigens (Ad5 and CMV), and cytokine pro­
duction and proliferation capacity were analyzed by multipa­
rametric flow cytometry.
Representative flow cytometry profiles for S. pneumoniae 
and K. pneumoniae in one healthy donor and one CVID pa­
tient are shown in Fig. 1 (A and B). The cumulative data for 
all the bacteria­ and virus­specific CD4 T cell responses 
mentioned above showed that the frequencies of IFN­– 
and IL­2–producing bacteria­specific but not virus­specific 
Table 2. Clinical manifestation of CVID patients
Subjects LPS Autoimmunity IBD Lymphoid hyperplasia Granulomatous disease
CVID-1 No No No Yes (intestinal) No
CVID-2 Yes No No No No
CVID-3 Yes No No No No
CVID-4 Yes No No No No
CVID-5 Yes Yes No Yes (intestinal) Yes
CVID-6 No No No No No
CVID-7 No No No No No
CVID-8 No No No No No
CVID-9 Yes Yes No No Yes
CVID-10 No No No No No
CVID-11 Yes No No Yes (intestinal) No
CVID-12 Yes Yes No No No
CVID-13 No Yes Yes Yes (intestinal) Yes
CVID-14 Yes Yes No No Yes
CVID-15 Yes Yes (diabetes) No Yes (intestinal) No
CVID-16 Yes No No Yes (intestinal) No
CVID-17 No No No Yes (intestinal) No
CVID-18 No No No Yes (intestinal) No
CVID-19 Yes No No Yes (intestinal) No
CVID-20 Yes No No Yes (intestinal) No
CVID-21 Yes No No Yes (intestinal) No
CVID-22 No No No Yes (intestinal) No
CVID-23 No No No Yes (intestinal) No
CVID-24 No No No Yes (intestinal) No
CVID-25 No No No Yes (intestinal) No
CVID-26 No Yes (diabetes) No Yes (intestinal) No
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Detection of endotoxins in plasma of CVID patients
We postulated that the CD4 T cell dysfunction observed in 
CVID patients could be related to bacterial translocation. To 
test this hypothesis, bacterial translocation was evaluated using 
an enzymatic reaction detecting the presence of endotoxins in 
virus­specific T cell responses between CVID patients and 
healthy controls is consistent with the lack of clinical evi­
dence of increased reactivation of chronic virus infections 
in CVID patients (Cunningham­Rundles and Bodian, 1999; 
Raeiszadeh et al., 2006).
Figure 1. Functional impairment of bacteria-specific CD4 
T cells in CVID patients. CD4 T cells from healthy subjects (HS) 
or CVID patients were stimulated with S. pneumoniae and  
K. pneumoniae bacteria antigen preparations and expression of 
IL-17A, IL-2, TNF, and IFN- were measured by flow cytometry. CD4 
T cell responses to -CD3/-CD28 (polyclonal stimulation) or 
unstimulated (negative control) are also shown (n = 30 healthy 
individuals and 12 CVID patients). (A and B) Representative flow 
plots from one healthy subject (#882; A) and one representative 
CVID patient (CVID-11; B) are shown. (C) Frequencies of bacteria-
specific and virus-specific CD4 T cells producing IFN-, IL-2, TNF, 
or IL-17A were calculated. (D) CD4 T cells from healthy subjects 
(n = 10) and CVID patients (n = 12) were stimulated with  
S. pneumoniae and K. pneumoniae and proliferation was measured 
by CFSE dilution. Unstimulated cell cultures (negative control) 
and cell cultures stimulated with SEB (positive control) are also 
shown. (E) Percentage of bacteria- and virus-specific CD4 T cell 
proliferation. P-values were calculated using Student’s t test.  
*, P < 0.05; **, P < 0.001; ***, P < 0.0001.
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both the plasma of CVID patients with serum levels of IgGs 
<4.9 mg/ml (n = 8) and in healthy individuals (n = 10; Roger 
et al., 2009). All CVID patients with serum IgG levels 
<4.9 mg/ml had measurable levels of endotoxin, whereas en­
dotoxin was not detected in healthy controls (0%; P < 0.0001; 
Fig. 2 A). Consistent with this, the levels of endotoxin were sig­
nificantly higher in CVID patients with IgG levels <4.9 mg/ml 
as compared with healthy subjects (P = 0.0027; Fig. 2 B). 
Therefore, these results demonstrate the occurrence of bacte­
rial translocation in CVID patients with low serum IgG levels.
Increased PD-1 expression on CD4 T cells of CVID patients
On the basis of the occurrence of microbial translocation 
and the observed selective dysfunction of bacteria­specific 
CD4 T cells, we speculated that the functional impairment of 
bacteria­specific CD4 T cells might result from the modulation 
of the expression of co­inhibitory molecules (Barber et al., 2006; 
Day et al., 2006; Petrovas et al., 2006; Trautmann et al., 2006; 
McMahan et al., 2010). We therefore evaluated the expres­
sion of PD­1, 2B4, CD160, signaling lymphocytic activation 
molecule (SLAM), CTLA­4, LAG­3, and TIM­3 on CD4 
Figure 2. Endotoxin levels in CVID patients correlate with IgG 
levels. (A) Proportion of healthy subjects (n = 10) and CVID patients  
(n = 9) with endotoxemia as measured by limulus assay test. (B) Levels  
of endotoxin in plasma of healthy individuals and CVID patients were 
measured by limulus assay test. P-values were calculated using either  
2 analysis for comparison of positive proportions or Student’s t test for 
multiple comparisons. *, P < 0.05; ***, P < 0.0001. [IgG], concentration of 
IgG in mg/ml.
Figure 3. CD4 T cells of CVID patients 
express high levels of PD-1. CD4 T cells from 
healthy subjects (n = 30) and CVID patients  
(n = 21) were analyzed for the expression of PD-1, 
SLAM, CD160, 2B4, CTLA-4, LAG-3, and TIM-3 
by flow cytometry. (A) Representative flow 
plots showing expression of PD-1 and SLAM or 
CD160 and 2B4 in one representative healthy 
subject (#MP) and one CVID patient (CVID-05). 
(B) Cumulative data showing co-inhibitory 
molecule expression (healthy subjects [HS],  
n = 30; CVID patients, n = 21). (C) Percentages of 
PD-1CXCR5, PD-1+CXCR5, PD-1CXCR5+, 
and PD-1+CXCR5+ (blood Tfh-like cells) CD4  
T cell populations (HS, n = 10; CVID patients,  
n = 10). (D) Percentages of naive (CD45RA+CCR7+), 
central memory (CD45RACCR7+), effector 
memory (CD45RACCR7), and terminally dif-
ferentiated effector memory (CD45RA+CCR7) 
CD4 T cells among total CD4 T cells (HS, n = 26; 
CVID patients, n = 21). (E) Percentage of CD57-
expressing CD4 T cells. (F) Percentage of CD69-, 
CD25-, HLA-DR–, and PD-1–expressing CD4  
T cells (HS, n = 10; CVID patients, n = 9). P-values 
were calculated using either one-way  
ANOVA (Kruskal-Wallis test) or Student’s  
t test for multiple comparisons. *, P < 0.05;  
**, P < 0.001; ***, P < 0.0001.
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T cells of CVID patients (n = 21) and healthy subjects (n = 30) 
by flow cytometry. CD4 T cells of CVID patients expressed 
significantly higher levels of PD­1 as compared with healthy 
subjects (P < 0.0001; Fig. 3, A and B). No significant differ­
ences were observed in the expression of 2B4, CD160, SLAM, 
CTLA­4, LAG­3, and TIM­3 (P > 0.05; Fig. 3, A and B).
Morita et al. (2011) showed that blood PD­1+CXCR5+ 
CD4 T cells shared functional properties with germinal cen­
ter T follicular helper (Tfh) cells, i.e., IL­21 production and 
induction of Ig production from autologous B cells. There­
fore, the expression of CXCR5 and PD­1 was evaluated in 
memory (CD45RA) CD4 T cell populations of CVID pa­
tients and healthy subjects to determine whether increased 
PD­1 expression was associated with CXCR5 expression. As 
shown in the cumulative data (Fig. 3 C), the frequencies of 
PD­1+CXCR5+ CD4 T cell populations were not signifi­
cantly different between CVID patients and healthy individuals 
(P = 0.2704). These data demonstrate that the increased ex­
pression of PD­1 in memory CD4 T cells observed in CVID 
patients is not associated with CXCR5 expression, thus indi­
cating that blood Tfh­like cell populations are not increased 
in CVID patients.
T cell dysfunction may also result from skewed T cell dif­
ferentiation or immunosenescence (Champagne et al., 2001; 
Deeks et al., 2012). T cell differentiation (based on CCR7 and 
CD45RA expression; Sallusto et al., 1999) and immunosenes­
cence (based on CD57 expression; Petrovas et al., 2006) markers 
were then investigated. No significant differences were observed 
in the frequency of central memory (CD45RACCR7+), 
effector memory (CD45RACCR7), and terminally differ­
entiated effector memory (CD45RA+CCR7) CD4 T cells 
Figure 4. Bacteria-specific CD4 T cells of CVID  
patients express high levels of PD-1. Percentages of 
bacteria-specific and virus-specific CD4 T cells expressing 
PD-1 were analyzed by flow cytometry. (A) Representative 
flow plots from one healthy subject (#MP) and one CVID 
patient (CVID-06). (B) Proportion of antigen-specific CD4  
T cells expressing PD-1 in healthy subjects (n = 9) and CVID 
patients (n = 10). (C) Correlation between the percentage of 
PD-1–expressing total CD4 T cells and the percentage of  
PD-1–expressing bacteria-specific CD4 T cells. Statistical signifi-
cance (p-values) in B were calculated using Student’s t test 
and in C using Spearman’s rank correlations. ***, P < 0.0001.
Figure 5. PD-1 blockade restores bacteria-specific CD4 T cell prolif-
eration in CVID patients. Blood mononuclear cells were labeled with CFSE 
and stimulated with bacteria- or virus-derived antigens in the presence  
or in the absence of –PDL-1/2 Abs and proliferation was measured in CD4- 
positive T cells at day 6. (A) Representative flow cytometry profiles of bacteria-
specific and virus-specific CD4 T cell proliferation in one representative CVID 
patient (CVID-02). Unstimulated cell cultures (negative control) and cell cul-
tures stimulated with SEB (positive control) are also shown. (B and C) Per-
centage of bacteria-specific (B) or virus-specific (C) proliferating CD4 T cells 
in the presence or absence of –PD-L1/2 Abs in CVID patients (n = 10). 
P-values were calculated using paired Student’s t test. *, P < 0.05.
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PD­1–PD­L1/2 signaling restored the proliferation of bacteria­
specific CD4 T cells in CVID patients at levels comparable 
to healthy subjects (P > 0.05).
(Fig. 3 D), and in that of CD57­expressing CD4 T cells 
between CVID patients and healthy subjects (P > 0.05; 
Fig. 3 E). A trend toward a skewed effector memory phenotype 
was observed only in three CVID patients. Because increased 
PD­1 expression may also be associated with T cell activation 
(Cellerai et al., 2010), the expression of activation markers, 
such as CD69, CD25, and HLA­DR, was assessed by flow 
cytometry but no significant differences were observed in 
the expression of these markers between CVID patients and 
healthy subjects (P > 0.05; Fig. 3 F).
As shown above, CD4 T cell dysfunction was found to be 
restricted to bacteria­specific CD4 T cells. It was then impor­
tant to determine whether the increased PD­1 expression was 
also predominantly restricted to bacteria­specific CD4 T cells. 
To assess and to compare the expression of PD­1 in bacteria­ 
and virus­specific CD4 T cells, we took advantage of a re­
cently described flow cytometry–based technique by Haney 
et al. (2011) which allows the identification and characteriza­
tion of antigen­specific CD4 T cells on the basis of the ex­
pression of membrane TNF (mTNF). Levels of PD­1 were 
significantly higher in bacteria­specific but not virus­specific 
CD4 T cells in CVID patients as compared with healthy sub­
jects (P < 0.0001; Fig. 4, A and B). In addition, the percentage 
of PD­1–expressing total CD4 T cells directly correlated with 
the percentage of PD­1–expressing bacteria­specific CD4 
T cells (r = 0.9543, P < 0.0001; Fig. 4 C). Collectively, these 
results indicate that the selective dysfunction of bacteria­ 
specific CD4 T cells results from the increased expression of 
the negative regulatory receptor PD­1 which is likely driven 
by microbial translocation.
PD-1 blockade restores bacteria-specific  
CD4 T cell proliferation
PD­L1 and PD­L2 are the ligands to PD­1 and are ex­
pressed on different cell types (Ito et al., 2007). PD­L1 is 
expressed on hematopoietic and nonhematopoietic cells, 
whereas PD­L2 is expressed on DCs and macrophages (Ito 
et al., 2007). To delineate the involvement of PD­1–PD­L1/2 
signaling in the impaired proliferation of bacteria­specific 
CD4 T cells, blood mononuclear cells of CVID patients (n = 10) 
were labeled with CFSE and stimulated with bacteria­ or 
virus­derived antigens in the presence or in the absence of 
anti–PD­L1/2 blocking antibodies or isotype controls (Petrovas 
et al., 2006; Trautmann et al., 2006; Yamamoto et al., 2011). 
The frequency of proliferating CD4 T cells (CD3+CD4+ 
CFSElow cells) was assessed at day 6. Representative flow 
cytometry profiles (Fig. 5 A) and cumulative data (Fig. 5 B) 
showed that the blockade of PD­1–PD­L1/2 signaling sig­
nificantly increased bacteria­specific—and also, to a lower 
extent, virus­specific—CD4 T cell proliferation (1.83­fold 
increase, P = 0.0024, and 1.07­fold increase, P = 0.0396, 
respectively; Fig. 5, B and C), supporting the involvement of 
PD­1–PD­L1/2 signaling as the primary cause of the im­
paired bacteria­specific CD4 T cell proliferation. Isotype 
control treatment did not have any effect on virus­specific 
CD4 T cell proliferation capacity. Of note, the blockade of 
Figure 6. PD-1 expression directly influences CD4 T cell cytokine 
profile in CVID patients. Blood mononuclear cells from CVID patients  
(n = 12) were stimulated with bacteria antigen preparations and cytokine 
production (IL-17A, IL-2, TNF, and IFN-) by CD4 T cells from CVID pa-
tients with low frequency (<30%; white circles) or high frequency (>30%; 
black circles) of PD-1 expression was assessed by polychromatic flow 
cytometry. (A) Proportion of bacteria-specific CD4 T cells producing TNF, 
IFN-, IL-2, and/or IL-17A. All the possible combinations of the responses 
are shown on the x axis and the percentage of the functionally distinct 
cell populations within the bacteria-specific CD4 T cell populations are 
shown on the y axis. The pie chart summarizes the data, and each slice 
corresponds to the fraction of CD4 T cells with a given number of func-
tions within the responding CD4 T cell population. Statistical analyses of 
the global cytokine profiles (pie charts) were performed by partial permu-
tation tests using the SPICE software as previously described (Roederer  
et al., 2011). Bars correspond to the fractions of different functionally 
distinct T cell populations within the total CD4 T cells. Red stars indicate 
statistical significance (*, P < 0.05) calculated using a Student’s t test.  
(B) Correlations between the percentage of PD-1–expressing CD4 T cells 
and the percentage of TNF-, IFN-–, IL-2–, or IL-17A–producing bacteria-
specific CD4 T cells (n = 12). Statistical significance (p-values) in B was 
calculated using Spearman’s rank correlations.
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levels of PD­1 (<30%) were significantly more polyfunctional 
(produced TNF, IFN­, and IL­2; P = 0.003; Fig. 6 A). Interest­
ingly, the proportion of triple TNF/IFN­/IL­2, dual IFN­/
IL­2, and dual TNF/IL­2 was significantly increased at the ex­
pense of single TNF­producing CD4 T cell populations in 
bacteria­specific CD4 T cell responses of CVID patients with 
PD­1–expressing CD4 T cells <30% as compared with those 
with PD1 expression >30% (P < 0.05; Fig. 6 A). Finally, the 
proportion of IL­2–producing bacteria­specific CD4 T cells 
negatively correlated with the frequency of PD­1–expressing 
CD4 T cells (r = 0.7060, P = 0.0041; Fig. 6 B).
PD-1 expression influences CD4 T cell cytokine profile
We then tested whether PD­1 expression on CD4 T cells may 
influence the CD4 T cell cytokine profile in CVID patients. In 
this regard, the cytokine profile of bacteria­specific CD4 T cells 
was correlated with PD­1 expression. The qualitative differ­
ences in the cytokine profile of bacteria­specific CD4 T cells 
on the basis of PD­1 expression are shown in Fig. 6. The cu­
mulative data showed that the cytokine profile of bacteria­ 
specific CD4 T cells expressing higher levels of PD­1 (>30%) 
was skewed toward single TNF­producing bacteria­specific CD4 
T cells, whereas bacteria­specific CD4 T cells expressing lower 
Figure 7. Efficient IVIG treatment restores CD4 T cell 
functions. IgG concentration, endotoxin level, PD-1 expres-
sion, and bacteria-specific CD4 T cell proliferation were 
assessed on sera and blood mononuclear cells from CVID 
patients. (A) Correlation of endotoxin levels with IgG levels 
(n = 40). (B) Reduction of endotoxin levels after Ig substitution. 
(C) Representative flow cytometry profiles of bacteria-
specific CD4 T cells expressing PD-1 in one representative CVID 
patient (CVID-08) at two time points. (D) Proportion of 
antigen-specific CD4 T cells expressing PD-1. (E) Representa-
tive flow cytometry profiles of bacteria-specific and virus-
specific proliferating CD4 T cells in one representative CVID 
patient (CVID-8) at two time points. Unstimulated cell cul-
tures (negative control) and cell cultures stimulated with SEB 
(positive control) are also shown. (F) Cumulative data of 
bacteria-specific CD4 T cell proliferation in treated CVID 
patients (n = 8). (G) Cumulative data of PD-1 expression in 
CD4 T cells in treated CVID patients (n = 8). (H) Correlation 
between bacteria-specific CD4 T cell proliferation and PD-1 
expression. P-values were calculated using a paired Student’s 
t test for multiple comparisons in B, D, and F or Spearman 
Rank test for correlation in A and G. *, P < 0.05.
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on CD4 T cells was also significantly reduced after 11 mo of 
IVIG treatment (P = 0.008; Fig. 7 G). Finally, we showed that 
the PD­1 expression level in CD4 T cells inversely correlated 
with the percentage of bacteria­specific CD4 T cell prolifera­
tion (r = 0.7345, P = 0.0011; Fig. 7 D). Collectively these 
data demonstrate that IVIG treatment induces resolution of 
bacterial translocations in the large majority of patients and re­
stores CD4 T cell proliferation.
DISCUSSION
In the present study, we have hypothesized that recurrent 
bacterial infections observed in CVID patients were responsi­
ble for the CD4 T cell impairment and we postulated that the 
CD4 T cell dysfunction was predominantly restricted to 
bacteria­specific CD4 T cells. In this regard, the clinical picture 
of CVID patients is complicated by recurrent bacterial infec­
tions (Van der Hilst et al., 2002; Park et al., 2008; Hong et al., 
2010), whereas no increase in the frequencies of acute (i.e., 
influenza) or reactivation of chronic viral infections (i.e., EBV 
or CMV; Raeiszadeh et al., 2006) has been reported.
Our results indicate that the impairment of CD4 T cell 
functions was selective to bacteria­specific but not virus­
specific T cell responses. CD4 T cells from CVID patients 
had reduced capacities to produce cytokines (IL­2 and IFN­) 
and to proliferate. The defect in the production of IL­2 may 
be responsible for the defects of T cell proliferation described 
in CVID patients together with the exhaustion associated 
with the PD­1 expression. The defect in the production of 
IFN­ may not necessarily be responsible for the direct 
impairment of CD4 T cells but for the defective bactericidal 
activity of macrophages through the defective activation of 
macrophages by impaired Th1 CD4 T cells from CVID pa­
tients. Of note, no significant differences were observed in 
CD4 T cell differentiation, immunosenescence, and activa­
tion markers between CVID patients and healthy individuals 
in our cohort of patients. An increase in the proportion of 
activation markers has been recently reported in CD4 T cells 
of CVID patients (Paquin­Proulx et al., 2013a).
The severe impairment in CD4 T cell function found in 
CVID patients was reminiscent of that observed in patients 
with HIV infection (Day et al., 2006; Petrovas et al., 2006; 
Trautmann et al., 2006). The CD4 T cell dysfunction in HIV 
infection has been at least partially attributed to the chronic 
immune stimulation resulting from microbial translocation 
(Brenchley et al., 2004; Brenchley and Douek, 2008). We 
therefore investigated the presence of microbial translocation 
in CVID patients through the determination of endotoxemia 
levels. Interestingly, we found increased endotoxemia levels 
in patients with CVID which inversely correlated with IgG 
serum levels. The continuous leak of bacteria in the gut and 
bronchial mucosa might be responsible for the exhaustion of 
bacteria­specific CD4 T cells. In support of our hypothesis, 
CD4 T cells of CVID patients showed significant increased 
expression of PD­1 as compared with healthy individuals. 
We also provided evidence that PD­1 was selectively in­
creased in bacteria­specific CD4 T cells, as indicated by the 
Effective IVIG treatment restores  
the CD4 T cell functional impairment
As shown above, the detection of endotoxemia was observed 
in CVID patients with hypogammaglobulinemia. On the 
basis of these findings, we have determined the correlation 
between endotoxemia and IgG serum levels, and the effects 
of Ig replacement therapy on endotoxemia and, in turn, on 
CD4 T cell functions. We show that endotoxemia inversely 
correlated with the serum levels of IgG (r = 0.5988, P < 
0.0001; Fig. 7 A). With regard to serum IgA levels, we did 
not find any correlation between serum IgA levels and endo­
toxemia (r = 0.066 and P = 0.6930). Furthermore, with re­
gard to the frequencies of B cell populations in the CVID 
patients (we have used the Euro class definition; Wehr et al., 
2008), no association was observed between the proportion 
of CD27+ B cells (or any other B cell population) and endo­
toxemia (unpublished data). Finally, endotoxemia did not 
correlate with inflammatory bowel diseases (Table 2).
Furthermore, the presence of endotoxin was assessed in 
CVID patients (n = 8) before and after IVIG therapy. The 
IgG titers consistently increased >4.9 mg/ml after IVIG ther­
apy (Fig. 7 B). Endotoxemia levels consistently and signifi­
cantly decreased after initiation of therapy, suggesting that 
IVIG therapy was associated with efficient reduction of bac­
terial translocation in CVID patients (P = 0.0437; Fig. 7 B). 
IVIG therapy might potentially influence endotoxemia levels 
through the presence of anti­LPS IgG antibodies. To exclude 
the potential impact of anti­LPS antibodies in the detection/
concentration of LPS, we determined the effects of treating 
in vitro the serum of an untreated CVID patient positive for 
the detection of LPS with IVIG at a final IgG concentration 
of 10 mg/ml. A CVID patient with low LPS levels, i.e., 
53 pg/ml, was selected to have the best experimental conditions 
to detect any potential interference of the IVIG treatment. 
Of note, serum treatment with IVIGs did not significantly 
reduce LPS concentration (P = 0.7802; unpublished data). 
These data indicate that IVIG treatment is unlikely to influ­
ence the detection of LPS in the sera of CVID patients.
We then investigated the effects of continuous IVIG ther­
apy in restoring normal CD4 T cell function. To address this 
issue, PD­1 expression on bacteria­specific CD4 T cells was 
assessed in blood mononuclear cells of IVIG­treated CVID pa­
tients (n = 6) at two time points (spaced by 8.8 mo on average). 
Representative flow cytometry profiles and cumulative data 
showed that IVIG treatment significantly reduced PD­1 ex­
pression on bacteria­specific CD4 T cells (P = 0.0120; Fig. 7, 
C and D). In addition, the proliferation capacity of bacteria­
specific CD4 T cells was assessed in blood mononuclear cells 
of IVIG­treated CVID patients (n = 8) at two time points 
(spaced by 11.2 mo on average). Representative flow cytome­
try profiles and cumulative data showed that IVIG treatment 
significantly restored bacteria­specific CD4 T cell proliferation 
(P = 0.0165; Fig. 7, E and F). Of note, IVIG therapy restored 
the proliferation of bacteria­specific CD4 T cells in CVID pa­
tients at levels comparable to healthy subjects (P > 0.05; un­
published data). In addition, the percentage of PD­1 expression 
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>7 mg/ml. Whether the dose of Ig replacement should be in­
creased to achieve higher IgG serum levels in CVID patients 
has been debated (Cunningham­Rundles, 2010). One could 
speculate that higher IgG concentration may be beneficial to 
CVID patients by reducing the bacterial infections and likely 
by reducing the general degree of inflammation. In support of 
this assumption, it has been recently shown that high­dose 
therapy of IVIG (range 1–3 g/kg) leads to antiinflammatory 
effects via FcRII­mediated IL­33 production by dendritic 
cells that induces IL­4 secretion by basophils and promotes 
antiinflammatory (Th2) responses (Anthony et al., 2011). In 
conclusion, the present study provides new insights in the 
mechanisms responsible for the CD4 T cell impairment pres­
ent in patients with CVID and has identified endotoxemia 
as a novel marker to monitor the therapeutic response to Igs 
trans­complementation.
MATERIALS AND METHODS
Study groups. In the present study, 26 CVID patients (Table 1) and 30 
healthy individuals have been enrolled. Blood samples from the healthy 
subjects were obtained from the Blood Bank of Lausanne, Switzerland. 
CVID patients were either recruited at the Centre Hospitalier Universitaire 
Vaudois (Lausanne, Switzerland) or at the Hôpital Henri­Mondor Albert­
Chenevier (Paris, France). The Institutional Review Boards of both institu­
tions approved this study and informed consent was obtained from each 
individual enrolled. The diagnosis of CVID was formulated according to 
the European Society for ImmunoDeficiencies (ESID) and Pan­American 
Group for Immunodeficiency (PAGID) criteria. The clinical manifestations 
of CVID include predominantly recurrent bacterial infections, noninfec­
tious lung and digestive pathologies, autoimmune diseases, and increased 
susceptibility to cancers (Table 2). The medical records of the patients stud­
ied were analyzed to determine the clinical symptoms before the diagnosis 
of CVID. Most patients suffered from recurrent bacterial infections several 
years before the diagnosis of CVID was confirmed. All patients suffered 
from recurrent sinusitis and antibiotic therapy was administered several 
times per year. Recurrent lower respiratory tract infections (bronchitis and 
pneumonia) were present in 19 out of 26 patients. One patient experienced 
bacterial meningitis. Gastrointestinal complaints were identified in 3 pa­
tients, mainly recurrent diffuse abdominal pain and diarrhea. An intestinal 
parasite (Strongyloides stercoralis) was found in 1 patient. 7 out of 26 patients 
had autoimmune manifestations, 16 out 26 patients had intestinal lymphoid 
hyperplasia, and 4 out of 26 granulomatosis disease.
Cell isolation. Peripheral blood mononuclear cells (PBMCs) were isolated 
by Ficoll gradient (GE Healthcare). After centrifugation (300 g, 20 min), 
PBMC ring was harvested in PBS­EDTA 2 mM (Laboratorium Dr Bichsel 
AG, and Ambion for PBS and EDTA, respectively). Cells were either used 
directly or cryopreserved in liquid nitrogen for future experiments.
Antibodies. The following antibodies were used: allophycocyanin (APC)­H7–
conjugated anti­CD3 (clone SK7), FITC­conjugated anti­CD4 (clone RPA­T4), 
APC­conjugated anti­CD4 (clone RPA­T4), Pacific blue (PB)–conjugated 
anti­CD4 (clone RPA­T4), APC­H7–conjugated anti­CD8 (clone SK1), 
PerCP­Cy5.5–conjugated anti­CD8 (clone SK1), PerCP­conjugated anti­ 
CD69 (clone L78), PECy7­conjugated anti­CD279 (PD­1; clone EH12.1), 
APC­conjugated anti­TNF (MAbII), FITC­conjugated anti­CD25 (OX­39), 
PECy­conjugated anti­TNF (clone MabII; BD); energy coupled dye (ECD)–
conjugated anti­CD3 (clone UCHT1), ECD­conjugated anti­CD45RA 
(clone 2H4), ECD­conjugated anti­CD4 (clone T4; Beckman Coulter); 
PECy5.5­conjugated anti­2B4 (CD244; clone C1.7), PE­conjugated anti­
SLAM (CD150; clone A12), PB­conjugated anti­CD57 (clone HCD57), Alexa 
Fluor 647–conjugated anti­CD160 (clone BY55; BioLegend); EFluor 
increased expression of PD­1 on mTNF­positive CD4 T cells. 
Further demonstration that the expression of PD­1 was the 
primary cause of the exhaustion and of the associated func­
tional impairment of bacteria­specific CD4 T cells was ob­
tained by the finding that restoration of proliferation occurred 
after the blockade of PD­1–PD­L1 axis.
Levels of endotoxin inversely correlated with IgG serum 
levels, thus indicating that hypogammaglobulinemia was poten­
tially responsible for microbial translocation (Brenchley et al., 
2004; Brenchley and Douek, 2008) and increased endotoxemia 
in CVID patients. This hypothesis was supported by the finding 
that IVIG treatment induced the reduction of endotoxemia.
CVID patients were also longitudinally followed up to 
determine whether IVIG treatment had any impact on the 
restoration of CD4 T cell functions. Interestingly, IVIG treat­
ment was associated with lower PD­1 expression and restoration 
of polyfunctional cytokine responses, and increased prolifera­
tion in response to stimulation with bacteria­derived anti­
gens. No more differences in the percentage of proliferating 
bacteria­specific CD4 T cells were observed between healthy 
subjects and CVID patients after treatment with anti­PDL 
antibodies in vitro and IVIG therapy.
Collectively, the results on the relationship between IgG 
levels and endotoxemia and the impact of IVIG therapy on the 
levels of endotoxemia indicate that endotoxemia may be instru­
mental to monitor the response to therapy in CVID patients. 
Because suppression of endotoxemia is also associated with the 
improvement of bacteria­specific CD4 T cell functions, the 
measure of endotoxemia may also serve as an indirect marker of 
restoration of bacteria­specific CD4 T cell functions.
Our results favor the following model that is not exclu­
sive of CVID but likely applicable to any pathological condi­
tion causing Ig deficiency. Recurrent bacterial infections in 
CVID patients result from defective levels of IgA in the 
mucosa and of IgG that circulates and passively diffuses 
through the oropharyngeal or gut mucosa (Butcher et al., 1975; 
Lieberman et al., 1979; Coruh and Mason, 1980; Morris 
et al., 1980; Brandtzaeg et al., 1985). Ig deficiency is associ­
ated with microbial translocation, which causes selective ex­
haustion of bacteria­specific CD4 T cells as indicated by the 
up­regulation of the co­inhibitory receptor PD­1 in these 
cells. In turn, PD­1–expressing bacteria­specific CD4 T cells 
show reduced proliferation capacity and defective production 
of cytokines (IL­2 and IFN­). The treatment with IVIG re­
stores bacteria­specific CD4 T cell responses, likely due to 
the reduction of bacteria­derived antigen load which, in turn, 
results in reduction of the magnitude of chronic stimulation 
and PD­1 expression on bacteria­specific CD4 T cells. The 
restoration of CD4 T cell functions is consistent with the 
similar effects observed in chronic viral infections, such as 
HIV or hepatitis C virus, after suppression of viral load with 
antiviral therapy (Day et al., 2006; Trautmann et al., 2006).
The current recommendation of IgG trans­complementation 
is to reach plasmatic IgG serum levels of 6 mg/ml by admin­
istering 400 mg/kg Igs every 3–4 wk (Orange et al., 2006). 
More than 95% of healthy individuals have IgG serum levels 
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T cell differentiation (anti–CD3­APC H7, anti–CD4­PB, anti–CD8­Efluor­
625NC, anti–CD45RA­ECD, and anti–CCR7­FITC), T cell activation, 
and immunosenescence (anti–CD3­ECD, anti–CD4­APC, anti–CD8­
APC­H7, anti–CD69­PerCP, anti–CD25­FITC, anti–PD­1­PeCy7, anti– 
HLADR–Alexa Fluor 700, and anti–CD57­PB). Data were acquired by 
flow cytometry.
mTNF production. Blood mononuclear cells (106 cells/ml) were stimu­
lated (18 h) with heat­inactivated bacteria pool (5 × 107 CFU/ml) or Ad5 
(1 µg/ml) in complete RPMI containing TAPI­0 (10 µM; EMD Millipore) 
and APC­conjugated anti­TNF (0.2 mg/ml) as previously described (Haney 
et al., 2011). PHA (Sigma­Aldrich) was used as positive control and unstimu­
lated cells as negative control. At the end of the stimulation period, dead cells 
were stained using the violet LIVE/DEAD stain kit (4°C, 15 min). Cells were 
stained (4°C, 15 min) with anti–CD3­ECD, anti–CD4­FITC, anti–CD8­
APC­H7, and anti–PD­1 PeCY7. Data were analyzed by flow cytometry.
Endotoxin measurement. Endotoxins were quantified in plasma or sera 
using limulus assay test (Charles River). In brief, plasma were diluted (1/50) 
in sterile water (Laboratorium Dr Bichsel AG) and LPS was assessed using 
Endosafe­Point Test system (Charles River).
Ig quantification. Total IgG quantification was performed in the Immu­
nology and Allergy diagnostic laboratory by nephelometry.
Statistical analyses. Statistical significance (p­values) was derived from 2 
analyses for comparison of positive proportions. P­values were derived using 
one­way ANOVA (Kruskal­Wallis test), followed by Student’s t test for 
multiple comparisons. Spearman’s rank test was used for correlations. The 
analyses of multiple comparisons were taken into account for the calculation 
of statistical significance.
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